Thermo Fisher Scientific (TMO) Receivables - Net (2009 - 2026)

Thermo Fisher Scientific (TMO) has reported Receivables - Net for 18 consecutive years, with $9.5 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Receivables - Net rose 9.97% year-over-year to $9.5 billion; the trailing twelve-month figure through Jun 2026 stood at $9.5 billion (up 9.97% YoY), and the FY2025 full-year result was $8.9 billion, up 8.66% from the prior year.
• Receivables - Net improved to $9.5 billion in Q2 2026 per TMO's latest filing, from $9.2 billion in the prior quarter.
• Across five years, Receivables - Net topped out at $9.5 billion in Q2 2026 and bottomed at $7.7 billion in Q4 2022.
• Historically, Receivables - Net has averaged $8.3 billion across 5 years, with a median of $8.2 billion in 2023.
• The sharpest annual moves came in 2022 and 2024: Receivables - Net surged 42.04% in 2022, then decreased 1.37% in 2024.
• Over 5 years, Receivables - Net stood at $8.1 billion in 2022, then advanced by 1.31% to $8.2 billion in 2023, then retreated by 0.36% to $8.2 billion in 2024, then climbed by 8.66% to $8.9 billion in 2025, then increased by 6.19% to $9.5 billion in 2026.
• According to Business Quant data, Receivables - Net over the past three periods registered $9.5 billion, $9.2 billion, and $8.9 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.